How well does Zydelig work?

Zydelig demonstrates efficacy in relapsed CLL, FL, and SLL, primarily improving response rates and progression-free survival.

Clinical Efficacy and Therapeutic Outcomes of Zydelig

Zydelig, as monotherapy or in combination with rituximab, has shown significant clinical benefit in patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). In CLL, Zydelig plus rituximab significantly prolongs progression-free survival compared to rituximab alone. 

In FL and SLL, Zydelig achieves notable overall response rates, though improvement in overall survival or disease-related symptoms has not been established. Continued approval for FL and SLL is contingent upon confirmatory trials. Efficacy in other malignancies or pediatric populations is not specified in the description.